Insider Trading › ASND › Insiders
Ascendis Pharma A/S
ASND·Nasdaq·Insider activity
$226.05
-1.98 (-0.87%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
ASND
Insider purchases and sales on the price
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ASNDS&P 500 (rebased)
Insider BuyInsider SellForm 144 · planned sale
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
In the last 180 days, ASND insiders filed 9 purchases ($777K) and 3 sales ($5.5M) on the open market, by 5 insiders. Newest filing Sep 9, 2026 (28 days ago).
Net Insider Buying by Quarter
Shares bought (+) or sold (−) on the open market by ASND insiders · Form 4 · last two years
On Record
$777KPurchases · 180 days
$5.5MSales · 180 days
12Open-market transactions on record
5Insiders filing · 180 days
Purchases (code P) and sales (code S) of ASND common stock reported on Form 4, with Form 5 annual catch-ups. Grants, option exercises, gifts and tax withholding are not shown. Dollars are shares × the stated price; a price outside anything the stock traded at that day is withheld (n/c).
Insider Transactions
12 on record · newest trade first
AllPurchasesSalesOfficers & directors
| Insider | Type | Shares | Price | Value | Held after | Traded | Filed | |
|---|---|---|---|---|---|---|---|---|
| Bodenhoff MadsSVP & PAO | Sale | −3,000 | $270.19 | $811K | 0direct | Sep 8, 2026 | Sep 9, 2026 | Form 4 ↗ |
| HOLTUG LARSDirector · Director | Sale | −236 | $264.13 | $62K | 4,000direct | Sep 2, 2026 | Sep 3, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector · Director | Purchase | +900 | $246.91 | $222K | 2,900direct | Aug 14, 2026 | Aug 18, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector · Director | Purchase | +1,100 | $245.85 | $270K | 2,000direct | Aug 14, 2026 | Aug 18, 2026 | Form 4 ↗ |
| SMITH SCOTT THOMASEVP & Chief Financial Officer | Purchase | +100 | $219.00 | $22K | 4,367direct | Jun 2, 2026 | Jun 2, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +100 | $223.50 | $22K | 900direct | May 29, 2026 | Jun 1, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +200 | $222.30 | $44K | 800direct | May 29, 2026 | Jun 1, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +200 | $223.76 | $45K | 600direct | May 29, 2026 | Jun 1, 2026 | Form 4 ↗ |
| SMITH SCOTT THOMASEVP & Chief Financial Officer | Purchase | +250 | $223.32 | $56K | 4,267direct | May 29, 2026 | Jun 1, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +200 | $239.37 | $48K | 400direct | May 26, 2026 | May 27, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +200 | $236.24 | $47K | 200direct | May 26, 2026 | May 27, 2026 | Form 4 ↗ |
| JENSEN FLEMMING STEENSee Remarks | Sale | −19.5K | $238.49 | $4.6M | 0direct | May 11, 2026 | May 12, 2026 | Form 4 ↗ |
Source: SEC EDGAR Form 4 and Form 5 filings, SEC's quarterly bulk dataset through Jun 30, 2026, and KeyVex's half-hourly read of new filings since. Every row links its filing. Amendments are marked. Nothing here is a recommendation. All insider activity, market-wide →